ClinicalTrials.gg
CompletedNCT04208152Updated Aug 6, 2020

A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects

A Phase 1 interventional study of anle138b and Placebo in Healthy Volunteers, sponsored by MODAG GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-06.

Sponsored by MODAG GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.

Enrollment
99th of 183
68 · median 80
Started
2019
with 21 others
Phase 1
26 of 246
2 open now
Registered
135th of 246
by date

Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 99th largest by enrollment of the 183 interventional ones that give a count, is one of 22 that started in 2019, is one of 26 in phase 1, and was the 135th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Parkinson Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.

Read the detailed description

This is a single-centre, study of double-blind, randomised, placebo-controlled single ascending doses (SAD) and multiple ascending doses (MAD) of anle138b in healthy subjects in study Parts 1 and 2. In study Part 3 the effect of food (FES) on the safety and PK of anle138b in healthy subjects is examined.

In the SAD cohorts, subjects will be randomly assigned to receive a single oral dose of active investigational medicinal product (IMP) or matching placebo in a sequential escalating manner with sufficient time planned between dose groups to allow interim review of the data.

In the MAD cohorts, subjects will be randomly assigned to receive oral doses of active IMP or matching placebo once daily (QD) for 7 days, in a sequential escalating manner with sufficient time planned between dose groups to allow interim review of the data.

In the FES, the effect of food on the safety and PK of anle138b is explored by administering a single dose of IMP after a high-fat breakfast. Subjects will be randomly assigned to one of 2 treatment sequence to receive anle138b in the fed or fasted state over 2 periods.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • anle138b
  • alpha-Synuclein
  • Oligomer modulator
  • Parkinson Disease
  • Multiple System Atrophy
  • Neurodegenerative diseases
  • Alzheimer Disease
  • Tauopathies
  • Amyloid
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or women of no child bearing potential
  2. Age 18 to 55 years of age at the time of signing
  3. (BMI) of 18.5 to 30.0 kg/m2 as measured at screening
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent
  6. Must agree to adhere to the requirements defined in Section 9.4
  7. In the investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1.
  2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
  3. Subjects who have previously been enrolled in this study. Subjects who have taken part in Part 1 are not permitted to take part in Part 2 or Part 3; subjects who have taken part in Part 2 are not permitted to take part in Part 3.
  4. History of any drug or alcohol abuse in the past 2 years.
  5. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  6. A confirmed positive alcohol breath test at screening or admission.
  7. Current smokers and those who have smoked within the last 12 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  8. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
  9. Females of including those who are pregnant or lactating (all female subjects must have a negative urine pregnancy test at screening and serum pregnancy test on admission). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) or is (had no menses for 12 months without an alternative medical cause and a serum follicle stimulating hormone concentration ≥40 IU/L).
  10. Subjects with pregnant or lactating partners.
  11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening.
  12. abnormal clinical chemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1). Subjects with Gilbert's Syndrome are allowed. In addition the and gamma glutamyl transferase (GGT) concentrations should not exceed the (ULN) at screening and admission.
  13. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1) at screening or admission.
  14. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
  15. Evidence of renal impairment at screening, as indicated by an estimated of \<70 mL/min using the Cockcroft-Gault equation.
  16. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator.
  17. Serious adverse reaction or serious to any drug or the IMP .
  18. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
  19. Donation or loss of greater than 400 mL of blood within the previous 3 months.
  20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than 4 g of paracetamol per day or HRT) in the 14 days before IMP administration (See Section 11.4). Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the PI.
  21. Failure to satisfy the investigator of fitness to participate for any other reason.
  22. In Part 3, subjects must be able to eat 90% of the US Food and Drug Administration (FDA)-approved high-fat breakfast, including bacon.
  23. Subjects with a previous history of difficulty in swallowing tablets or capsules, or an anticipated problem with swallowing a large number of capsules.
  24. Blood pressure (supine) at Screening or admission outside the range: 90 to 140 mmHg for subjects \<45 years or 90 to 160 mmHg for subjects >45 years for systolic BP or 40 to 90 mmHg for diastolic BP; and pulse rate outside the range of 40 to 100 bpm, unless deemed not clinically significant by the investigator and the sponsor's medical monitor.
  25. Subjects with a history of cholecystectomy or gall stones.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Active comparator
    anle138b

    Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD

    Drug: anle138b

  • Placebo comparator
    placebo

    Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD

    Drug: Placebo

Interventions

  • capsule containing excipient and anle138b

  • DrugPlacebo

    matching placebo capsule containing excipient

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of anle138b (Part 1)

    Adverse events (AEs)

    Time frame: Day 1 to day 30 post dose

  2. Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with single ascending doses of anle138b (Part 1)

    clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase

    Time frame: Day 1 to day 7 post dose

  3. Incidence of treatment-emergent changes in vital signs in healthy volunteers with single ascending doses of anle138b (Part 1)

    Blood pressure, heart rate, oral temperature

    Time frame: Day 1 to day 7 post dose

  4. Incidence of treatment-emergent ECG changes in healthy volunteers with single ascending doses of anle138b (Part 1)

    Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)

    Time frame: Day 1 to day 7 post dose

  5. Incidence of treatment-emergent changes in physical examination in healthy volunteers with single ascending doses of anle138b (Part 1)

    physical examination findings

    Time frame: Day 1 to day 7 post dose

  6. Incidence of treatment-emergent adverse events in healthy volunteers with multiple ascending doses of anle138b (Part 2)

    Adverse events (AEs)

    Time frame: Day 1 to day 30 post dose

  7. Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with multiple ascending doses of anle138b (Part 2)

    clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase

    Time frame: Day 1 to day 7 post dose

  8. Incidence of treatment-emergent changes in vital signs in healthy volunteers with multiple ascending doses of anle138b (Part 2)

    Blood pressure, heart rate, oral temperature

    Time frame: Day 1 to day 7 post dose

  9. Incidence of treatment-emergent ECG changes in healthy volunteers with multiple ascending doses of anle138b (Part 2)

    Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)

    Time frame: Day 1 to day 7 post dose

  10. Incidence of treatment-emergent changes in physical examination in healthy volunteers with multiple ascending doses of anle138b (Part 2)

    physical examination findings

    Time frame: Day 1 to day 7 post dose

  11. Incidence of treatment-emergent adverse events in healthy volunteers with a single dose of anle138b both the fasted and fed state (Part 3)

    Adverse events (AEs)

    Time frame: Day 1 to day 30 post dose.

  12. Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3)

    clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase

    Time frame: Day 1 to day 7 post dose

  13. Incidence of treatment-emergent changes in vital signs in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3)

    Blood pressure, heart rate, oral temperature

    Time frame: Day 1 to day 7 post dose

  14. Incidence of treatment-emergent ECG changes in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3)

    Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)

    Time frame: Day 1 to day 7 post dose

  15. Incidence of treatment-emergent changes in physical examination in healthy volunteers with single ascending doses of anle138b both in the fasted and in the fed state (Part 3)

    physical examination findings

    Time frame: Day 1 to day 7 post dose

Secondary outcomes

  1. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Time prior to the first measurable concentration of anle138b. Time prior to the first measurable concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  2. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Time of maximum observed concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  3. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Maximum observed concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  4. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Area under the curve from 0 time to 24 h post-dose of anle138b.

    Time frame: From dosing to 48 hours post dosing

  5. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Area under the curve from 0 time to the last measurable concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  6. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Area under the curve from 0 time extrapolated to infinity of anle138b levels.

    Time frame: From dosing to 48 hours post dosing

  7. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Percentage of area under the curve (0-inf) extrapolated beyond the last measurable concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  8. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Slope of the apparent elimination phase of anle138b.

    Time frame: From dosing to 48 hours post dosing

  9. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Apparent elimination half-life of anle138b.

    Time frame: From dosing to 48 hours post dosing

  10. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Mean residence time from 0 time to the last measurable concentration after extravascular administration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  11. Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state

    Mean residence time extrapolated to infinity after extravascular administration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  12. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state

    Time of maximum observed concentration of anle138b

    Time frame: Day 1 to day 9

  13. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state

    Maximum observed concentration of anle138b

    Time frame: Day 1 to day 9

  14. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state

    Area under the curve over the dosing interval from time 0 to tau of anle138b

    Time frame: Day 1 to day 9

  15. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state

    Slope of the apparent elimination phase (last dose only) of anle138b

    Time frame: Day 7 to day 9

  16. Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state

    Apparent elimination half-life (last dose only) of anle138b

    Time frame: Day 1 to day 9

  17. Oral pharmacokinetics (PK) of single (Part 1) and multiple (Part 2) ascending doses of anle138b in the fasted state

    Accumulation Ratio based on Cmax repeated dose /Cmax single dose of anle138b

    Time frame: Day 1 to day 9

  18. Oral pharmacokinetics (PK) of single (Part 1) and multiple (Part 2) ascending doses of anle138b in the fasted state

    Accumulation Ratio based on area under the curve (0 tau) repeated dose/AUC(0 tau) single dose of anle138b

    Time frame: Day 1 to day 9

  19. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states.

    Maximum observed concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  20. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states.

    Area under the curve from 0 time to the last measurable concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

  21. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states

    Area under the curve from 0 time extrapolated to infinity of anle138b levels.

    Time frame: From dosing to 48 hours post dosing

  22. Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states

    Percentage of area under the curve (0-inf) extrapolated beyond the last measurable concentration of anle138b.

    Time frame: From dosing to 48 hours post dosing

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Publications

  • Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bahr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Botzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125(6):795-813. doi: 10.1007/s00401-013-1114-9. Epub 2013 Apr 19. PubMed 23604588 ↗
  • Levin J, Schmidt F, Boehm C, Prix C, Botzel K, Ryazanov S, Leonov A, Griesinger C, Giese A. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 2014 May;127(5):779-80. doi: 10.1007/s00401-014-1265-3. Epub 2014 Mar 11. No abstract available. PubMed 24615514 ↗
  • Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N. Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019 Feb;34(2):255-263. doi: 10.1002/mds.27562. Epub 2018 Nov 19. PubMed 30452793 ↗
  • Wegrzynowicz M, Bar-On D, Calo' L, Anichtchik O, Iovino M, Xia J, Ryazanov S, Leonov A, Giese A, Dalley JW, Griesinger C, Ashery U, Spillantini MG. Depopulation of dense alpha-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathol. 2019 Oct;138(4):575-595. doi: 10.1007/s00401-019-02023-x. Epub 2019 May 31. PubMed 31165254 ↗
  • Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, Leonov A, Kleinknecht A, Goricke B, Weishaupt JH, Weckbecker D, Reiner AM, Zinth W, Levin J, Ehninger D, Remy S, Kretzschmar HA, Griesinger C, Giese A, Fuhrmann M. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015 Nov;130(5):619-31. doi: 10.1007/s00401-015-1483-3. Epub 2015 Oct 6. PubMed 26439832 ↗
  • Martinez Hernandez A, Urbanke H, Gillman AL, Lee J, Ryazanov S, Agbemenyah HY, Benito E, Jain G, Kaurani L, Grigorian G, Leonov A, Rezaei-Ghaleh N, Wilken P, Arce FT, Wagner J, Fuhrmann M, Caruana M, Camilleri A, Vassallo N, Zweckstetter M, Benz R, Giese A, Schneider A, Korte M, Lal R, Griesinger C, Eichele G, Fischer A. The diphenylpyrazole compound anle138b blocks Abeta channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol Med. 2018 Jan;10(1):32-47. doi: 10.15252/emmm.201707825. PubMed 29208638 ↗
  • Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, Wegrzynowicz M, Dalley JW, Langer S, Ryazanov S, Leonov A, Griesinger C, Schmidt F, Weckbecker D, Prager K, Matthias T, Giese A. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine. 2022 Jun;80:104021. doi: 10.1016/j.ebiom.2022.104021. Epub 2022 Apr 29. PubMed 35500536 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Aug 2020, 7 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 204 studies reached it within 19 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2019
First posted
Dec 23, 2019
StartActual
Dec 6, 2019
Primary completionActual
Aug 4, 2020
CompletionActual
Aug 4, 2020
Last update
Aug 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04208152
Lead sponsor
MODAG GmbH
Collaborators
Quotient Sciences, Aptuit
Responsible party
Sponsor
First posted
Dec 23, 2019
Start date
Dec 6, 2019
Primary completion
Aug 4, 2020
Completion
Aug 4, 2020
Last update
Aug 6, 2020

Study contacts

Nand Singh, BSc, MD, DPM, MFPM
principal investigator · Quotient Sciences Mere Way Ruddington Fields Ruddington Nottingham NG11 6JS, UK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emrusolmin

Start the discussion